Objective To evaluate the efficacies of 2 different administration methods with recombinant human granulocyte colony- stimulating factor (rhG- CSF) on treatment of leukopenia in the elderly patients with soft tissue sarcoma after chemotherapy. Methods Eighty- two elderly patients with pathologically verified soft tissue sarcoma admitted in our hospital during January 2010 and January 2014 were enrolled in our study. After chemotherapy regimen of MAID (mesna, doxorubicin, ifosfamide, and dacarbazine), they were randomized into Group A and Group B. The patients of Group A received 2.5 μg/kg rhG- CSF within 24 h after chemotherapy, once per day, for 14 d or till the white blood cell (WBC) count over 4.0×109/L. While those from Group B were monitored for their blood routine after chemotherapy, and received 5 μg/kg rhG- CSF per day only when they were at grade Ⅱ bone marrow suppression, once per day for 7 d or till the WBC count over 4.0×109/L. Minimal WBC count，recovery maximal WBC count, recovery time, treatment duration and treatment times were observed to evaluate the two administration methods. Results (1)There were no significant differences in general information between the two groups (P>0.05). (2) No statistical significance was seen in the minimal WBC count between the 2 groups (P>0.05). But Group B had shorter recovery time and higher recovery maximal WBC count than Group A (P<0.05). (3) The treatment durations were obviously shorter and the treatment times were significantly lower in Group B than in Group A (P<0.05). Conclusion The method of applying rhG- CSF in group B with high dose and short treatment duration indeed improves WBC counts in the patients with chemotherapy- induced myelosuppression, and it also alleviates the pain after rhG- CSF injection. Thus, it is worthy of clinical application.